Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Operating Expenses (2021 - 2025)

Senti Biosciences has reported Operating Expenses over the past 5 years, most recently at $18.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 15.41% year-over-year to $18.7 million; the TTM value through Dec 2025 reached $68.8 million, up 12.72%, while the annual FY2025 figure was $68.8 million, 12.72% up from the prior year.
  • Operating Expenses for Q4 2025 was $18.7 million at Senti Biosciences, up from $16.9 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $44.2 million in Q3 2023 and troughed at $1178.0 in Q1 2021.
  • A 5-year average of $16.4 million and a median of $16.3 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 1091750.59% in 2022 and later plummeted 65.59% in 2024.
  • Year by year, Operating Expenses stood at $11.7 million in 2021, then surged by 44.31% to $16.9 million in 2022, then increased by 10.95% to $18.7 million in 2023, then dropped by 13.54% to $16.2 million in 2024, then rose by 15.41% to $18.7 million in 2025.
  • Business Quant data shows Operating Expenses for SNTI at $18.7 million in Q4 2025, $16.9 million in Q3 2025, and $16.8 million in Q2 2025.